Gabather Overview
- Founded
-
2014
- Status
-
Public
- Employees
-
4
- Stock Symbol
-
GABA
- Share Price
-
$0.35
- (As of Friday Closing)
Gabather General Information
Description
Gabather AB is engaged in developing novel drugs to treat several diseases originating in the central nervous system. It has four main focus areas anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as cognition-enhancing treatments, including for Alzheimer's disease.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
STO
Primary Office
- Skeppsbron 2, 1 TR
- 211 20 Malmo
- Sweden
+46 070-777 00 00
Gabather Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.35 | $0.39 | $0.33 - $0.76 | $5.32M | 13.6M | 16.4K | -$0.11 |
Gabather Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 5,714 | 4,629 | 5,434 | 6,908 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (1,455) | (1,978) | (1,622) | (1,500) |
| Net Income | (1,455) | (1,979) | (1,621) | (1,510) |
| Total Assets | 1,023 | 1,701 | 3,806 | 4,927 |
| Total Debt | 0 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Gabather Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Gabather Patents
Gabather Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210087193-A1 | Triazoloquinazolinone synthesis | Active | 19-Dec-2017 | 0000000000 | |
| US-11434243-B2 | Triazoloquinazolinone synthesis | Active | 19-Dec-2017 | 0000000000 | 0 |
| EP-3752507-A1 | Triazoloquinazolinone synthesis | Pending | 19-Dec-2017 | 0000000000 | |
| US-20110092525-A1 | Gabaa receptor modulators | Active | 04-Apr-2008 | 0000000000 | |
| US-8809355-B2 | Gabaa receptor modulators | Active | 04-Apr-2008 | C07D487/04 |
Gabather Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Michael-Robin Witt Ph.D | Acting Chief Executive Officer | ||
| Ola Skanung | Chief Financial Officer | ||
| Mogens Nielsen | CSO |
Gabather Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| Gunilla Ekström Ph.D | Self | Board Member | 000 0000 |
| Karl Svensson | Self | Board Member | 000 0000 |
| Olov Sterner | Gabather | Board Member | 000 0000 |
| Svein Arild Mathisen | Self | Board Member | 000 0000 |
Gabather Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
